Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific. It operates in two segments, Medical, and Nuclear & Safety. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as product handling, medical imaging furniture, and rehabilitation products. This segment improves the quality and safety of cancer care delivery; and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include radiation measurement and monitoring solutions, reactor instrumentation and control detectors, imaging systems and cameras, and waste management systems; laboratory and scientific analysis systems comprising gamma/alpha spectroscopy, alpha/beta counting, specialty detectors, and spectroscopy software; radiation measurement and health physics instrumentation; and contamination and clearance monitors. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.

Mirion Technologies Inc. Class A

Mirrabooka Investments Ltd ( ($AU:MIR) ) has issued an update. Mirrabooka Investments reported a decline in its net tangible asset backing per shar...

Mirrabooka NTA Slips as Mid and Small-Cap Portfolio Holds Course

Medmira ( ($TSE:MIR) ) just unveiled an update. MedMira reported second-quarter fiscal 2026 results marked by weaker revenue and a wider net loss, ...

MedMira Expands McKesson Partnership as Quarterly Revenue Falls and Loss Widens

J.P. Morgan analyst Tomohiko Sano maintained a Buy rating on Mirion Technologies today and set a price target of $27.00. Sano covers the Industrial...

J.P. Morgan Remains a Buy on Mirion Technologies (MIR)

MIRA Pharmaceuticals, Inc. ( ($MIRA) ) just unveiled an update. On March 23, 2026, MIRA Pharmaceuticals reported new preclinical data showing that ...

MIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55

Mirrabooka Investments Ltd ( ($AU:MIR) ) has issued an update. Mirrabooka Investments Limited has reported an estimated pre-tax net tangible asset ...

Mirrabooka flags $2.80 pre-tax NTA per share, above market price

Mirrabooka Investments Ltd ( ($AU:MIR) ) just unveiled an update. Mirrabooka Investments Limited has reported an estimated pre-tax net tangible ass...

Mirrabooka posts estimated pre-tax NTA of $2.96 per share

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mirum Pharmaceuticals (MIRM – Research Report) and Talkspace (TAL...

Current Quarter	$0.1	Next Quarter	$0.12
Current Year	$0.5	Next Year	$0.61
QoQ Growth	+20.0%	YoY Growth	+22.0%
3Y EPS CAGR	-21.6%	Target Price	$28.50
Consensus	Buy	Upside	+50.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIR	$19.00	0.00%	2.95M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIR	$19.00	0%	2.95M
3
4
5
6

MIR

MIR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Mirion Technologies Inc. Class A Data in Excel

Get Mirion Technologies Inc. Class A Data in Excel